Actinium reported data from the Phase III SIERRA trial of Iomab-B for relapsed or refractory acute myeloid leukaemia (r/r AML ...

20, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted ...

On August 05, 2024, Actinium announced that after concluding both its clinical and Chemistry, Manufacturing and Controls ("CMC") interactions with the FDA regarding the BLA pathway for Iomab-B, the ...

NEW YORK – Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has shared results from its Phase 3 SIERRA trial for Iomab-B, a targeted radiotherapy aimed at conditioning patients ...

For developers and businesses looking to integrate the powerful capabilities of Claude AI into their applications, obtaining ...

NEW YORK – Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has shared results from its Phase 3 SIERRA trial for Iomab-B, a targeted radiotherapy aimed at conditioning patients for ...